Literature DB >> 29196995

Epigenetics and Preeclampsia: Programming of Future Outcomes.

Alberto Borges Peixoto1,2, Liliam Cristine Rolo1, Luciano Marcondes Machado Nardozza1, Edward Araujo Júnior3.   

Abstract

Pregnancy is known to induce rapid, progressive, and substantial changes to the cardiovascular system, ultimately facilitating successful pregnancy outcomes. Women who develop hypertensive disorders during pregnancy are considered to have "failed" the cardiovascular stress test of pregnancy and likely represent a subpopulation with inadequate cardiovascular accommodation. Preeclampsia is a serious complication with a myriad of manifestations in both mother and offspring. This pregnancy syndrome is a polygenic disease and has now been linked to a greater incidence of cardiovascular disease. Moreover, offsprings born to preeclamptic mothers exhibit an elevated risk of cardiovascular disease, stroke, and mental disorders during adulthood. This suggests that preeclampsia not only exposes the mother and the fetus to complications during pregnancy but also programs chronic diseases during adulthood in the offspring. The etiology of preeclampsia remains unknown, with various theories being suggested to explain its origin. It is primarily thought to be associated with poor placentation and entails excessive maternal inflammation and endothelial dysfunction. It is well established now that the maternal immune system and the placenta are involved in a highly choreographed cross talk that underlies adequate spiral artery remodeling required for uteroplacental perfusion and free flow of nutrients to the fetus. Although it is not clear whether immunological alterations occur early during pregnancy, studies have proposed that dysregulated systemic and placental immunity contribute to impaired angiogenesis and the onset of preeclampsia. Recently emerged strong evidence suggests a potential link among epigenetics, microRNAs (miRNAs), and pregnancy complications. This chapter will focus on important aspects of epigenetics, immunological aspects, and cardiovascular and vascular remodeling of preeclampsia.

Entities:  

Keywords:  Cardiovascular system; Epigenetic; Immunology; Preeclampsia; Remodeling

Mesh:

Year:  2018        PMID: 29196995     DOI: 10.1007/978-1-4939-7498-6_6

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

Review 1.  A Narrative Review of Placental Contribution to Adverse Pregnancy Outcomes in Women With Polycystic Ovary Syndrome.

Authors:  Angela S Kelley; Yolanda R Smith; Vasantha Padmanabhan
Journal:  J Clin Endocrinol Metab       Date:  2019-11-01       Impact factor: 5.958

2.  Assessment of myocardial injury in neonates born to pregnant women with pregnancy complicated by severe preeclampsia by myocardial work indices: a prospective study.

Authors:  Hui-Yun Chen; Tao Pan; Hong Li; Qiu-Qin Xu; Fang-Can Sun; Bing Han; Xin-Xian Gu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-02-15

3.  Increased uterine artery blood flow in hypoxic murine pregnancy is not sufficient to prevent fetal growth restriction†.

Authors:  Sydney L Lane; Alexandrea S Doyle; Elise S Bales; Ramón A Lorca; Colleen G Julian; Lorna G Moore
Journal:  Biol Reprod       Date:  2020-03-13       Impact factor: 4.285

4.  Association between RUNX3 gene polymorphisms in severe preeclampsia and its clinical features.

Authors:  Yanping Zhang; Tao Wang; Jin Jia; Wen Cao; Lei Ye; Yanyun Wang; Bin Zhou; Rong Zhou
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

5.  Decreased circUBAP2 Expression Is Associated with Preeclampsia by Limiting Trophoblast Cell Proliferation and Migration.

Authors:  Tingting Qi; Di Zhang; Xuting Shi; Minhui Li; Hongbin Xu
Journal:  Reprod Sci       Date:  2021-01-27       Impact factor: 3.060

6.  Myocardial Function in Offspring Aged 5 to 8 Years of Pregnancy Complicated by Severe Preeclampsia Measured by Two-Dimensional Speckle-Tracking Echocardiography.

Authors:  Huiyun Chen; Yu Gong; Fangcan Sun; Bing Han; Bingyuan Zhou; Jiali Fan; Xinxian Gu
Journal:  Front Physiol       Date:  2022-01-06       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.